Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia. Show more

Location: Toowong Tower, Toowong, QLD, 4066, Australia | Website: https://anteristech.com | Industry: Medical Instruments & Supplies | Sector: Healthcare


Market Cap

158.7M

52 Wk Range

$2.34 - $8.79

Previous Close

$4.40

Open

$4.36

Volume

40,208

Day Range

$4.30 - $4.50

Enterprise Value

133M

Cash

28.44M

Avg Qtr Burn

-18.34M

Insider Ownership

0.20%

Institutional Own.

44.68%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date